Study Reveals Role of ANKIB1 in Innate Immunity

The innate immune system relies on pattern recognition receptors (PRRs) to identify molecular patterns typical of invading bacteria and viruses. These detection systems trigger cascades that lead to the production of interferons, key molecules directing immune defenses. Yet the molecular pathway translating receptor activation into interferon production has remained unclear.

In a new study published in Nature Cell Biology, an international team led by Eva Rieser and Henning Walczak at the University of Cologne identified the enzyme ANKIB1 as a central regulator of this process. The researchers found that ANKIB1 catalyzes lysine 11-linked ubiquitination (K11-ubiquitin), forming a specific modification that acts as a scaffold for assembling protein complexes that activate type I and type III interferons. According to Dr. Rieser, “With the discovery of K11-ubiquitin as the third letter of the ubiquitin alphabet, we are now a decisive step closer to the deciphering of the ubiquitin code of cellular signaling.”

Experiments using cell cultures and mouse models revealed that the ANKIB1–K11‑Ubiquitin–OPTN–TBK1–IRF3 pathway is essential for recognizing viral infections. Mice lacking ANKIB1 were unable to produce sufficient interferons during infection with herpes simplex virus I, leading to fatal outcomes from an otherwise mild infection. Interestingly, the absence of ANKIB1 had the opposite effect in a model of severe inflammatory disease: mice that would otherwise die from excessive interferon signaling survived. These complementary results show that ANKIB1 plays a key role in both normal and pathological interferon responses.

Beyond infection control, the study points to implications for cancer. Professor Julian Pardo of the Aragón Health Research Institute noted that many tumors exploit chronic innate immune activation to create inflammation that weakens immune attack. Because ANKIB1 and K11-ubiquitin are pivotal in interferon induction, adjusting their activity might restore immune balance in tumors—either boosting interferon to reinforce anti-cancer responses or limiting it to prevent immune exhaustion.

The findings also shed light on neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where chronic interferon activity contributes to inflammation in the brain. By defining ANKIB1’s role in regulating these pathways, the researchers highlight new possibilities for targeted therapies. As Professor Walczak summarized, understanding the enzyme and the specific ubiquitin it generates could allow precise modulation of immune reactions without broadly suppressing the body’s essential defenses.